ZIOPHARM Oncology, Inc. (ZIOP) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
025M50M75M100M125M150M175M200MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Operating Expenses

Research And Development ExpensesGeneral And Administrative Expenses
08M15M22M30M38M45M52M60MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

EBITDA

EBITDA
-2M7M16M25M34M43M52M61M70MQ4 2024Q1 2025Q2 2025

EPS

Revenue Variation (%)

Revenue Variation
-300-262-225-187-150-112-74-371Q4 2024Q1 2025Q2 2025

Income Variation (%)

Revenue YoY Variation (%)

Income YoY Variation (%)

Price-to-Earning Ratio

P/E Ratio
-3-2-2-2-1-0001Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Income Breakdown

Operating IncomeTotal Other Income Expenses NetNet Income
025M50M75M100M125M150M175M200MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Per Share Metrics

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Expense Ratios

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
088175262350438525612700Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025
💰 Cash Flow Statement

Operating Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
025M50M75M100M125M150M175M200MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025

Free Cash Flow

Cash At End Of Period
0500K1M2M2M2M3M4M4MQ4 2024Q1 2025Q2 2025

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
06M12M19M25M31M38M44M50MQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025
🏦 Balance Sheet
📈 Key Metrics